全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

个人简历

教育经历
2002.09 - 2005.07 浙江大学药学院
1999.09 - 2002.07 广州中医药大学临床药理研究所
1995.09 - 1999.07 广州中医药大学中药学院
工作经历

2005年于University of Michigan任Research Fellow。2008年9月，于University of Michigan任Senior Research Fellow。2010年7月，于中国科学院上海药物研究所任研究员。2020年7月于中科中山药物创新研究院任研究员、课题组长、博士生导师。

现任International Journal of Pharmaceutics 编辑，Nano Letters, Journal of Controlled Release 编委；中药新药与临床药理、中国现代应用药学、药学进展编委，Acta Pharmaceutica Sinica B、药学学报青年编委。任中国药学会药剂学专业委员会委员，中国药学会纳米药物专业委员会委员。

研究领域

1.靶向给药系统；
2.透皮给药；
3.难溶性药物给药技术。

研究成果

采用先进药物递送技术提高体内药物输送效率，并对其转运特性及机制进行了研究，着重考察了在耐药肿瘤治疗的应用。多药耐药已成为了肿瘤治疗最大的障碍之一，本课题组的研究聚焦于耐药肿瘤治疗的这一关键科学问题，通过靶向调控肿瘤微环境的递药策略及治疗策略，致力于研究肿瘤相关巨噬细胞调控与肿瘤耐药（化疗耐药、分子靶向治疗耐药及免疫耐药）。

代表性论著（*：通讯作者）

1. Fang YF#, He Y#, Wu CH, Zhang M, Gu ZY, Zhang JX, Asrorov A.M., Xu Q*, Huang YZ*. Magnetism-Mediated Targeting Hyperthermia-Immunotherapy in “Cold” Tumor with CSF1R Inhibitor, Theranostics 2021, DOI: 10.7150/thno.57511

2. Wu AH, Chen YZ, Wang HR, Chang Y, Zhang M, Zhao PF, Tang YS, Xu Q*, Zhu ZZ, Huang YZ*. Genetically-Engineered “All-in-One” Vaccine Platform for Cancer Immunotherapy. Acta Pharmaceutica Sinica B 2021, online

3. Asrorov AM, Gu ZY, Li F*, Liu LY, Huang YZ*, Biomimetic Camouflage Delivery Strategies for Cancer Therapy. Nanoscale 2021, online

4. He ZD, Zhang M, Wang YH, He Y, Wang HR, Chen BF, Tu B, Zhu SQ, Huang YZ*. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta Pharmacologica Sinica. 2021. doi: 10.1038/s41401-020-00570-8

5. Zhao P, Zhang J, Wu A, Zhang M, Zhao Y, Tang Y, Wang B, Chen T, Li F, Zhao Q*, Huang YZ*. Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. Journal of Control Release 2021, 329:1249-1261

6. Zhen ZN, Zhang JX, Jiang JZ, He Y, Zhang WY, Mo XP, Kang XJ, Xu Q*, Wang B, Huang YZ*. Remodeling Tumor Immune Microenvironment (TIME) for Glioma Therapy Using Multi-Targeting Liposomal Codelivery. Journal for ImmunoTherapy of Cancer 2020: e000207

7. Zhao YG, Yang YT, Zhang JX, Wang R, Cheng BY, Kalambhe D, Wang YS, Gu ZY, Chen DY*, Wang B*, Huang YZ*. Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases. Acta Pharmaceutica Sinica B 2020: 1966-1976

8. Chen BF, Gao A, Tu B, Wang YH, Yu XL, Wang YS, Xiu YF, Wang B, Wan YK, Huang YZ* Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. Biomaterials 2020, 255:120187

9. Yin WM, Zhao YG, Kang XJ, Zhao PF, Fu X, Mo XP, Wang YH, Wan YK, Huang YZ*. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation. Theranostics 2020, 10(14): 6122

10. Tu B, He Y, Chen B, Wang Y, Gao Y, Shi M, Liu T, Asrorov AM, Huang YZ*. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment. Biomaterial Science 2020, 8:7166-7176

11. Wang HR, Huang YZ*. Combination Therapy Based on Nano Codelivery for Overcoming Cancer Drug Resistance. Medicine in Drug Discovery 2020: 100024

12. Chang Y, Jiang J, Chen W, Yang W, Chen L, Chen P, Shen J, Qian S, Zhou T, Wu LF, Hong L, Huang YZ*, Li F*. Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer. Applied Materials Today 2020, 18: 100492

13. Zhang JX, Zhao YG, Hou T, Zeng H, Kalambhe C, Wang B*, Shen X, Huang YZ*. Macrophage-based nanotherapeutic strategies in ulcerative colitis. Journal of Controlled Release 2020, 320:363 (Back cover)

14. Tu B, Zhang M*, Liu T, Huang YZ*. Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. Frontiers in Cell and Developmental Biology 2020, 8: 400

15. Asrorov AM, Gu Z, Min KA, Shin MC*, Huang YZ* Advances on Tumor-Targeting Delivery of Cytotoxic Proteins. ACS Pharmacology & Translational Science 2020, 3(1): 107

16. Ouyang X, Wang X, Kraatz HB, Ahmadi S, Gao J, Lv Y, Sun X*, Huang YZ*. A Trojan horse biomimetic delivery strategy using mesenchymal stem cells for PDT/PTT therapy against lung melanoma metastasis. Biomaterials Science 2020, 8: 1160